{"title": "Appealing for Efficient, Well Organized Clinical Trials on COVID-19", "doi": "10.1101/2020.03.05.20031476", "citation_id": "2020.03.05.20031476v1", "date": "2020-03-07", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.05.20031476", "abstract": "<p>The rapid emergence of clinical trials on COVID-19 stimulated a wave of discussion in scientific community. We reviewed the characteristics of interventional trials from Chinese Clinical Trial Registration (ChiCTR) and ClinicalTrials.gov. A total of 171 COVID-19-related interventional trials were identified on Feb 22nd, 2020. These trials are classified into 4 categories based on treatment modalities, including chemical drugs, biological therapies, traditional Chinese medicine treatments and other therapies. Our analysis focused on the issues of stage, design, randomization, blinding, primary endpoints definition and sample size of these trials. We found some studies with potential defects including unreasonable design, inappropriate primary endpoint definition, insufficient sample size and ethical issue. Clinical trials on COVID-19 should be designed based on scientific rules, ethics and benefits for patients.</p>", "twitter_description": "The rapid emergence of clinical trials on COVID-19 stimulated a wave of discussion in scientific community. We reviewed the characteristics of interventional trials from Chinese Clinical Trial Registration (ChiCTR) and ClinicalTrials.gov. A total of 171 COVID-19-related interventional trials were identified on Feb 22nd, 2020. These trials are classified into 4 categories based on treatment modalities, including chemical drugs, biological therapies, traditional Chinese medicine treatments and other therapies. Our analysis focused on the issues of stage, design, randomization, blinding, primary endpoints definition and sample size of these trials. We found some studies with potential defects including unreasonable design, inappropriate primary endpoint definition, insufficient sample size and ethical issue. Clinical trials on COVID-19 should be designed based on scientific rules, ethics and benefits for patients.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nThis study was funded by the National Natural Science Foundation of China (Grant No. 81872709) and Key Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (Grant No. 18KJA110004). The authors are grateful to Mr. Mingzhi Zhang, Miss Yuanping Yue and Mrs. Yue Wang for their help on preparing the manuscript.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll information used in this article can be retrieved directly from CHiCTR and CLinicalTrials.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.05.20031476v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.05.20031476v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.05.20031476v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/07/2020.03.05.20031476.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), CC BY-NC 4.0, as described at http://creativecommons.org/licenses/by-nc/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.05.20031476v1", "access_rights": "restricted", "authors": ["Yang Zhao", "Yongyue Wei", "Sipeng Shen", "Mingzhi Zhang", "Feng Chen"]}